Brief: Medesis Pharma And Transgene Announce Joint European Patent
Sept 1 (Reuters) - MEDESIS PHARMA SA ALMDP.PA :
* TODAY ANNOUNCED JOINT FILING WITH TRANSGENE OF A EUROPEAN
PATENT
PROTECTING A NOVEL THERAPEUTIC APPROACH TO INHIBIT INTERFERON
GENE EXPRESSION
* CNRS IS ALSO A STAKEHOLDER IN PATIENT
Source text for Eikon: ID:nNDL4fRT9v
Further company coverage: ALMDP.PA ; TRNG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs